Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues

Arcari, Andrea; Gryngarten, Mirta; Freire, Analía; Ballerini, Marı́a Gabriela; Ropelato, María Gabriela; Bergadá, Ignacio; Escobar, María Eugenia

doi:10.1186/s13633-016-0033-7

Cited by 23 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies of the effect of GnRHa treatment on weight gain among patients with CPP have revealed controversial findings. The results from the present study agree with findings from an earlier study 31) that revealed no significant changes in zBMI among 60 patients with CPP who received GnRHa treatment. Moreover, that study revealed that the patients who received GnRHa treatment had a lower zBMI after a long-term follow-up, compared to patients who did not receive the treatment.…”

Section: Discussionsupporting

confidence: 92%

The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty

et al. 2017

View full text Add to dashboard Cite

PurposeThe potential effect of gonadotropin-releasing hormone agonist (GnRHa) treatment on the weight of girls with central precocious puberty (CPP) remains a controversy. We investigated anthropometric changes during and after GnRHa treatment among girls with CPP.MethodsThis retrospective study evaluated data from 127 girls with CPP who received GnRHa treatment for ≥2 years. Height, weight, and body mass index (BMI) values were compared at the baseline (visit 1), after 1 year of GnRHa treatment (visit 2), the end of GnRHa treatment (visit 3), and 6–12 months after GnRHa discontinuation (visit 4).ResultsThe height z score for chronological age (CA) increased continuously between visit 1 and visit 4. No significant differences were observed in BMI z score for CA between visits 1 and 4. However, an increasing trend in the BMI z score for bone age (BA) was observed between visits 1 and 4. The numbers of participants who were of normal weight, overweight, and obese were 97, 22, and 8, respectively, at visit 1, compared to 100, 16, and 11, respectively, at visit 4 (P=0.48).ConclusionAmong girls with CPP, the overall BMI z score for CA did not change significantly during or after GnRHa treatment discontinuation, regardless of their BMI status at visit 1. However, the BMI z score for BA showed an increasing trend during GnRHa treatment and a decreasing trend after discontinuation. Therefore, long-term follow-up of BMI changes among girls with CPP is required until they attain adult height.

show abstract

Section: Discussionsupporting

confidence: 92%

The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty

et al. 2017

View full text Add to dashboard Cite

show abstract

“…5,[8][9][10] www.e-apem.org Furthermore, recent studies assessing girls with CPP reported that only girls in the normal weight group had increased BMI after GnRHa therapy; there were no changes in the overweight and obese groups. [11][12][13][14][15] Additionally, only a few studies have assessed the association between GnRHa therapy and change in BMI in boys with CPP. 5,16,17) Therefore, this study was designed to examine BMI changes in boys diagnosed with CPP over 2 years of GnRHa therapy.…”

Section: Introductionmentioning

confidence: 99%

Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy

Lim

Lee

Hwang

2020

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Thus they concluded that in ICPP girls the BMI increase under GnRH was inversely related to the pretreatment weight status .In the long term follow up no detrimental effect of GnRH on body weight was observed. BMI-SDS was lower in the treated than in untreated girls [70].…”

Section: Treatment Of Precocious Developmentmentioning

confidence: 69%

A Review on Update on Diagnosis and Therapeutic Management of Precocious Puberty’’ - A long with A Case Report

Kaur¹

2017

OAJG

View full text Add to dashboard Cite

Precocious Puberty (PP) is the attainment of secondary sex characters before the age of 8 in girls and 9 yrs in boys. It can be divided into Central PP(CPP)/True PP or Gonadotropin dependent PP and Gonadotropon independent PP(GIPP) or Pseudo PP. CPP is characterized by the premature activation of the hypothalamo-Pituitary-Gonadal Axis. Onset of secondary sex characteristics before age 8, which further progresses with increased growth velocity and bone age acceleration which ultimately ends in impaired adult height. Mutation studies have shown occasional mutations in KISS1. KISS1R, Makorin ring finger protein 3(MKRN3) genes as some of the genetic modifications. Treatment with Gonadotropin releasing hormone agonists remain the treatment of choice which helps in ultimate attainment of normal height till actual age of puberty. With further introduction of a yearly GnRH subcutaneous implant histerelin administration has become more convenient than the tedious monthly GnRH a in the form of leuprolide depot or decapeptyl depot. This review sums up the various causes of CPP and GIPP with an update of its management, differential diagnosis and a case report to highlight an example.

show abstract

Body mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues

Cited by 23 publications

References 31 publications

The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty

The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty

Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy

A Review on Update on Diagnosis and Therapeutic Management of Precocious Puberty’’ - A long with A Case Report

Contact Info

Product

Resources

About